$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000121390024013276 Filed on February 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q3
Revenue	$1.377M	$977.6K	$782.5K
YoY Change	195.45%	753.25%	-61.09%
Cost Of Revenue	$986.9K	$711.3K	$548.1K
YoY Change	127.04%	460.61%	553.7%
Gross Profit	$390.4K	$266.3K	$234.4K
YoY Change	1139.31%	-2263.92%	-87.84%
Gross Profit Margin	28.35%	27.24%	29.95%
Selling, General & Admin	$2.003M	$2.173M	$1.579M
YoY Change	9.99%	30.64%	-16.43%
% of Gross Profit	513.03%	816.13%	673.68%
Research & Development	$1.274M	$1.483M	$1.779M
YoY Change	-25.36%	-5.13%	23.72%
% of Gross Profit	326.21%	556.98%	759.15%
Depreciation & Amortization	$55.32K	$53.08K	$59.27K
YoY Change	44.32%	47.89%	77.35%
% of Gross Profit	14.17%	19.93%	25.29%
Operating Expenses	$3.277M	$3.657M	$3.399M
YoY Change	-7.11%	13.31%	2.15%
Operating Profit	-$2.886M	-$3.390M	-$3.165M
YoY Change	-17.44%	90.01%	126.02%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$31.01K	$45.58K	$29.62K
YoY Change	-215.23%	-11.63%	14.58%
Pretax Income	-$2.855M	-$3.345M	-$3.135M
YoY Change	-18.95%	93.04%	128.12%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.855M	-$3.345M	-$3.135M
YoY Change	-18.95%	93.04%	128.12%
Net Earnings / Revenue	-207.3%	-342.14%	-400.64%
Basic Earnings Per Share	-$0.11	-$0.14
Diluted Earnings Per Share	-$0.11	-$0.14	-$0.14
COMMON SHARES
Basic Shares Outstanding	25.93M shares	23.96M shares	23.92M shares
Diluted Shares Outstanding	25.91M shares	24.00M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.435M	$2.681M	$5.322M
YoY Change	-47.04%	-64.92%	-52.23%
Cash & Equivalents	$2.435M	$2.681M	$5.322M
Short-Term Investments			$0.00
Other Short-Term Assets	$407.8K	$21.32K	$263.8K
YoY Change	10.0%	-93.45%	-11.09%
Inventory	$1.312M	$1.609M	$1.727M
Prepaid Expenses		$238.6K	$263.7K
Receivables	$555.6K	$543.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.710M	$5.093M	$7.313M
YoY Change	-25.91%	-43.2%	-39.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$496.0K	$505.2K	$525.8K
YoY Change	-5.13%	50.89%	48.69%
Goodwill
YoY Change
Intangibles	$78.42K	$84.00K	$89.58K
YoY Change	-22.15%	-20.99%	-19.94%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$685.2K	$729.4K	$784.4K
YoY Change	-19.26%	5.21%	21.26%
TOTAL ASSETS
Total Short-Term Assets	$4.710M	$5.093M	$7.313M
Total Long-Term Assets	$685.2K	$729.4K	$784.4K
Total Assets	$5.395M	$5.822M	$8.097M
YoY Change	-25.12%	-39.73%	-36.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$780.8K	$760.0K	$685.1K
YoY Change	-18.1%	-11.8%	-26.15%
Accrued Expenses	$759.6K	$623.2K	$1.108M
YoY Change	27.25%	31.74%	54.72%
Deferred Revenue
YoY Change
Short-Term Debt	$121.9K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.540M	$1.383M	$1.793M
YoY Change	-0.64%	3.63%	-42.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$20.98K	$55.28K
YoY Change	-100.0%	-86.35%	-53.76%
Total Long-Term Liabilities	$0.00	$20.98K	$55.28K
YoY Change	-100.0%	-86.35%	-53.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.540M	$1.383M	$1.793M
Total Long-Term Liabilities	$0.00	$20.98K	$55.28K
Total Liabilities	$1.540M	$1.404M	$1.848M
YoY Change	-7.88%	-5.66%	-42.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.90M	-$66.00M	-$62.69M
YoY Change	22.82%	25.57%	23.33%
Common Stock	$26.32K	$24.83K	$23.93K
YoY Change	55.86%	52.91%	47.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.854M	$4.418M	$6.249M
YoY Change
Total Liabilities & Shareholders Equity	$5.395M	$5.822M	$8.097M
YoY Change	-25.12%	-39.73%	-36.85%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.855M	-$3.345M	-$3.135M
YoY Change	-18.95%	93.04%	128.12%
Depreciation, Depletion And Amortization	$55.32K	$53.08K	$59.27K
YoY Change	44.32%	47.89%	77.35%
Cash From Operating Activities	-$2.175M	-$3.809M	-$2.907M
YoY Change	-38.75%	9.08%	-385.6%
INVESTING ACTIVITIES
Capital Expenditures	$31.36K	$37.13K	$54.12K
YoY Change	-82.15%	222.54%	-181.76%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.080K
YoY Change	-100.0%	-100.0%	-100.14%
Cash From Investing Activities	-$31.36K	-$37.13K	-$50.04K
YoY Change	-101.72%	-346.41%	-98.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.960M	$1.205M	5.189M
YoY Change	196.12%	-7768.9%
NET CHANGE
Cash From Operating Activities	-2.175M	-$3.809M	-2.907M
Cash From Investing Activities	-31.36K	-$37.13K	-50.04K
Cash From Financing Activities	1.960M	$1.205M	5.189M
Net Change In Cash	-246.3K	-$2.642M	2.232M
YoY Change	-76.88%	-24.37%	-210.62%
FREE CASH FLOW
Cash From Operating Activities	-$2.175M	-$3.809M	-$2.907M
Capital Expenditures	$31.36K	$37.13K	$54.12K
Free Cash Flow	-$2.207M	-$3.847M	-$2.961M
YoY Change	-40.8%	9.78%	-373.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	001-40439
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	NeuroOne Medical Technologies Corporation
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Drive
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2023Q4	dei	City Area Code CityAreaCode	952
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	426-1383
CY2023Q4	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2023Q4	dei	Trading Symbol TradingSymbol	NMTC
CY2023Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25930926	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2680985	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5322493	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	543399	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1608657	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	259966	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263746	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5093007	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	7312925	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	83998	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140198	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505175	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2023Q4	us-gaap	Assets Assets	5822378	usd
CY2023Q3	us-gaap	Assets Assets	8097314	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	685104	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	623240	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1383240	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1792626	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20982	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	55284	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1404222	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1847910	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24831090	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24831090	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23928945	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23928945	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	24831	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	23929	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70424528	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68911778	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66031203	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62686303	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4418156	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5822378	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8097314	usd
CY2023Q4	us-gaap	Revenues Revenues	977649	usd
CY2022Q4	us-gaap	Revenues Revenues	114579	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	711335	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	126886	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	266314	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	-12307	usd
CY2022Q4	nmtc	Revenue From Collaboration RevenueFromCollaboration	1455188	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2173472	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1663737	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1483317	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1563496	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	3656789	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	3227233	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3390475	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1784352	usd
CY2023Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	45575	usd
CY2022Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	51583	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3344900	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1732769	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3344900	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23995610	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16230997	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	300181	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8171776	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	6249404	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1256271	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	37698	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	308638	usd
CY2023Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13559	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3344900	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4418156	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3344900	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1732769	usd
CY2023Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	58657	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35889	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	308638	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	300181	usd
CY2022Q4	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	20765	usd
CY2023Q4	nmtc	Noncash Lease Expense NoncashLeaseExpense	-28861	usd
CY2022Q4	nmtc	Noncash Lease Expense NoncashLeaseExpense	-26772	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	543399	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	62082	usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-118029	usd
CY2022Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	199016	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3780	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-74948	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	79527	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-154098	usd
CY2022Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1455188	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-518584	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-306125	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3809391	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3492253	usd
CY2022Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1473419	usd
CY2022Q4	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	1500000	usd
CY2023Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37131	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11512	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37131	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15069	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1256271	usd
CY2023Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	37698	usd
CY2022Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	15713	usd
CY2023Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13559	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1205014	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15713	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2641508	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3492897	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5322493	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8160329	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2680985	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4667432	usd
CY2022Q4	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets	88074	usd
CY2022Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66000000	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Management’s Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	259966	usd
CY2023Q4	nmtc	Number Of Days To Remedy Default NumberOfDaysToRemedyDefault	P90D
CY2023Q4	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
CY2022Q4	us-gaap	Royalty Expense RoyaltyExpense	37500	usd
CY2019Q4	us-gaap	Payments For Rent PaymentsForRent	6410	usd
CY2019Q4	nmtc	Increase Decrease In Rent IncreaseDecreaseInRent	7076	usd
CY2019Q4	nmtc	Base Rent Period BaseRentPeriod	P5M
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3M
CY2022Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2024-12-31
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	34070	usd
CY2022Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	32928	usd
CY2022Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	97536	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140198	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169059	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	153721	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184400	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.078	pure
CY2023Q4	nmtc	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Month LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonth	139969	usd
CY2023Q4	nmtc	Lessee Operating Lease Liability Payment Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo	21227	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	161196	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7475	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	153721	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132739	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20982	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	238645	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	263746	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21321	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263746	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1043906	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1202778	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	384659	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	343597	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180092	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	180311	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1608657	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1726686	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89577	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5579	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	83998	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5579	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	893237	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	860737	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	893237	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	860737	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	388062	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	334984	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505175	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525753	usd
CY2023Q4	us-gaap	Depreciation Depreciation	53078	usd
CY2022Q4	us-gaap	Depreciation Depreciation	30310	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	340490	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	874382	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132739	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129116	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	140011	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	104024	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	623240	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1107522	usd
CY2020Q4	us-gaap	Payments For Fees PaymentsForFees	2000000	usd
CY2022Q3	us-gaap	Payment For Management Fee PaymentForManagementFee	3500000	usd
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q4	nmtc	Transaction Price Associated With The Development Agreement TransactionPriceAssociatedWithTheDevelopmentAgreement	5400000	usd
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	100000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2022Q4	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	-1455188	usd
CY2023Q4	us-gaap	Revenues Revenues	977649	usd
CY2022Q4	us-gaap	Revenues Revenues	114579	usd
CY2023Q4	us-gaap	Advertising Expense AdvertisingExpense	49272	usd
CY2022Q4	us-gaap	Advertising Expense AdvertisingExpense	53026	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	308638	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300181	usd
CY2023Q4	nmtc	Shares Outstanding Percentage SharesOutstandingPercentage	0.13	pure
CY2024Q1	nmtc	Option Plan Shares OptionPlanShares	1051556	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1160669	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	73731	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.66
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814096	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1708427	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.12	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.535	pure
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.047	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.04	pure
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	56616	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	127446	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	55000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	182314	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2372540	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2023Q4	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	One
CY2023Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	14500000	usd
CY2022Q4	nmtc	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2023Q3	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	2600000	usd
CY2023Q4	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	4800000	usd
CY2024Q1	nmtc	Maximum Aggregate Common Stock Offering Price MaximumAggregateCommonStockOfferingPrice	9300000	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	868243	shares
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1256271	usd
CY2023Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	37698	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	103787	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16230997	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23995610	shares
CY2022Q4	nmtc	Stock Issued During Period Value Restricted Stock Unit Gross StockIssuedDuringPeriodValueRestrictedStockUnitGross		usd
CY2023Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2023Q4	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments		usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q4	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2023Q4	nmtc	Unpaid Deferred Issuance Costsoffset In Prepaids And Other Assets UnpaidDeferredIssuanceCostsoffsetInPrepaidsAndOtherAssets		usd
CY2023Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q4	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue		usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
0001213900-24-013276-index-headers.html	Edgar Link	pending
0001213900-24-013276-index.html	Edgar Link	pending
0001213900-24-013276.txt	Edgar Link	pending
0001213900-24-013276-xbrl.zip	Edgar Link	pending
f10q1223ex31-1_neuroone.htm	Edgar Link	pending
f10q1223ex31-2_neuroone.htm	Edgar Link	pending
f10q1223ex32-1_neuroone.htm	Edgar Link	pending
f10q1223ex32-2_neuroone.htm	Edgar Link	pending
f10q1223_neuroone.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20231231_cal.xml	Edgar Link	unprocessable
nmtc-20231231_def.xml	Edgar Link	unprocessable
nmtc-20231231_lab.xml	Edgar Link	unprocessable
nmtc-20231231_pre.xml	Edgar Link	unprocessable
f10q1223_neuroone_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q1 Form 10-Q Financial Statement

#000121390024013276 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2024 Q1 Form 10-Q Financial Statement

#000121390024013276 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc